Last $1.73 USD
Change Today -0.0399 / -2.25%
Volume 4.0K
CASI On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

casi pharmaceuticals inc (CASI) Snapshot

Open
$1.75
Previous Close
$1.77
Day High
$1.77
Day Low
$1.71
52 Week High
01/13/14 - $2.34
52 Week Low
11/13/13 - $1.45
Market Cap
46.8M
Average Volume 10 Days
13.5K
EPS TTM
$-0.21
Shares Outstanding
27.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CASI PHARMACEUTICALS INC (CASI)

Related News

No related news articles were found.

casi pharmaceuticals inc (CASI) Related Businessweek News

No Related Businessweek News Found

casi pharmaceuticals inc (CASI) Details

CASI Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops therapeutics to treat cancer and other diseases primarily in the United States and China. The company’s lead drug candidate includes ENMD-2076, an Aurora A and angiogenic kinase inhibitor for the treatment of cancer, which has completed Phase I studies in patients with advanced solid tumors, multiple myeloma, and leukemia, as well as it is completing data for a multi-center Phase II study in patients with platinum resistant ovarian cancer. Its other product candidates in development include 2-methoxyestrdiol, an orally active compound for autoimmune diseases; and MKC-1, an orally-active cell cycle inhibitor that has completed Phase II clinical trials for cancer treatment. The company name was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.

15 Employees
Last Reported Date: 03/21/14
Founded in 1991

casi pharmaceuticals inc (CASI) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: $285.2K
Principal Accounting Officer and Vice-Preside...
Total Annual Compensation: $175.1K
Chief Operating Officer, General Counsel and ...
Total Annual Compensation: $300.0K
Compensation as of Fiscal Year 2013.

casi pharmaceuticals inc (CASI) Key Developments

CASI Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

CASI Pharmaceuticals, Inc. reported earnings results for the second quarter and six months ended June 30, 2014. Net loss for the second quarter of 2014 was $1.6 million, or $0.06 per share. This compares with a net loss of $1.9 million, or $0.07 per share, for the same period last year. For the first six months of 2014 the net loss was $3.1 million, or $0.11 per share, compared with a net loss of $3.0 million, or $0.12 per share, for the first six months of 2013.

CASI Pharmaceuticals, Inc. Receives Approval from China's Food and Drug Administration to Conduct Phase II Clinical Trial with ENMD-2076

CASI Pharmaceuticals, Inc. announced that China's Food and Drug Administration (CFDA) has approved the Company's application to conduct a Phase II clinical trial in triple-negative breast cancer (TNBC) patients in China for its proprietary drug candidate, ENMD-2076. ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases, which have been shown to play important roles in the pathology of several cancers. ENMD-2076 has shown promising activity in Phase I clinical trials in solid tumor cancers including ovarian, breast, liver, renal and sarcoma, as well as in leukemia and multiple myeloma. CASI is completing a Phase II trial of ENMD-2076 in ovarian cancer. In addition, CASI is conducting a dual-institutional Phase II study of ENMD-2076 in triple-negative breast cancer, a Phase 2 study in advanced/metastatic soft tissue sarcoma and a Phase II ovarian clear cell carcinomas. ENMD-2076 has received orphan drug designation from the U.S. FDA for the treatment of ovarian cancer, multiple myeloma, acute myeloid leukemia, and hepatocellular carcinoma.

CASI Pharmaceuticals, Inc. Receives U.S. Orphan Drug Designation for the Use of ENMD-2076 to Treat Hepatocellular Carcinoma

CASI Pharmaceuticals, Inc. announced that its orally-active, Aurora A/angiogenic kinase inhibitor, ENMD-2076, has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of hepatocellular carcinoma (HCC). Orphan Drug designation is granted by the FDA Office of Orphan Products Development, which evaluates scientific and clinical data submissions from sponsors to identify and designate products as promising for rare diseases and to further advance scientific development of such promising medical products. Orphan Drug designation is granted to therapeutics treating rare diseases affecting less than 200,000 people in the U.S. The designation entitles the sponsor to seven years of market exclusivity as well as opportunities for additional funding and expert protocol assistance. ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases, which have been shown to play important roles in the pathology of several cancers. ENMD-2076 has shown promising activity in Phase I clinical trials in solid tumor cancers including ovarian, breast, liver, renal and sarcoma, as well as in leukemia and multiple myeloma. CASI is completing a Phase II trial of ENMD-2076 in ovarian cancer. In addition, CASI is conducting a dual-institutional Phase II study of ENMD-2076 in triple-negative breast cancer, a Phase II study in advanced/metastatic soft tissue sarcoma and a Phase II study in advanced ovarian clear cell carcinomas. ENMD-2076 has received orphan drug designation from the U.S. FDA for the treatment of ovarian cancer, multiple myeloma and acute myeloid leukemia.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CASI:US $1.73 USD -0.0399

CASI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergan Inc/United States $163.68 USD +1.57
Novartis AG SFr.85.90 CHF +3.55
Regeneron Pharmaceuticals Inc $350.46 USD +3.53
View Industry Companies
 

Industry Analysis

CASI

Industry Average

Valuation CASI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CASI PHARMACEUTICALS INC, please visit www.entremed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.